Better Therapeutics, Inc. Common Stock
BTTX
BTTX was delisted on the 15th of March, 2024.
16 hedge funds and large institutions have $3.11M invested in Better Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
74% more call options, than puts
Call options by funds: $647K | Put options by funds: $372K
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
14% more funds holding
Funds holding: 14 → 16 (+2)
12% more capital invested
Capital invested by funds: $2.77M → $3.11M (+$345K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$184K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$35.2K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$27.4K |
| 4 |
Millennium Management
New York
|
+$26K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$20.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$147K |
| 2 |
Two Sigma Investments
New York
|
-$100K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$23K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$14.1K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$18 |
BTTX Hedge Fund Activity: Q3 2022 in Review
16 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Better Therapeutics, Inc. Common Stock (BTTX) for Q3 2022, worth a combined $3.11M — up 12% from $2.77M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BTTX positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $184K. The largest seller was Morgan Stanley, exiting entirely with an estimated $147K sold.
- 16 institutional investors held Better Therapeutics, Inc. Common Stock (BTTX) as of Q3 2022, up from 14 in Q2 2022.
- Funds reported $3.11M of Better Therapeutics, Inc. Common Stock stock for Q3 2022, up 12% quarter-over-quarter.
- 4 funds opened new Better Therapeutics, Inc. Common Stock positions in Q3 2022 and 2 closed out, a net change of +2 holders.
- The largest Better Therapeutics, Inc. Common Stock buyer in Q3 2022 was Vanguard Group, an estimated $184K added.
- The largest Better Therapeutics, Inc. Common Stock seller in Q3 2022 was Morgan Stanley, an estimated $147K sold.
Based on aggregated 13F filings for Q3 2022.